You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Development of a vaccine to prevent Pneumocystis pneumonia

    SBC: NXT BIOLOGICS, INC.            Topic: NIAID

    Despite the fact that fungal diseases are an increasing clinical burden, particularly among immunocompromised patients, there are no anti-fungal vaccines approved for clinical use. The fungal opportunistic pathogen, Pneumocystis jirovecii is the causative agent of Pneumocystis pneumonia (PCP), which remains a serious AIDS-defining, opportunistic infection and is of increasing concern in persons re ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Development of Isotopically Labeled Glycoproteins for use as Internal Standards

    SBC: GlycoScientific, L.L.C.            Topic: 300

    Project Summary/Abstract The ability to accurately quantitate the glycan chains attached to glycoproteins has wide-ranging implications. Numerous studies over the past 40 years have demonstrated that abnormal glycosylation occurs in virtually all types of human cancers, and demonstrates the potential of using glycan markers in either a diagnostic or a prognostic manner. The glycosylation on recomb ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Feasibility Study of HIF2A Inhibitor PT2385 to Treat Muscle Strain Injury

    SBC: HAWA Therapeutics LLC            Topic: OD

    ABSTRACT Multi-PIs: Yin, A (HAWA Therapeutics) and Yin, H (UGA) Muscle strain injury (also called pulled muscle or eccentric contraction-induced muscle injury) is a common health problem affecting everyone in daily life. A mildly strained muscle may recover completely within one to two weeks; whereas moderate-to-severe muscle strains usually result in a prolonged and incomplete recovery with persi ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Multi NA-based influenza vaccines

    SBC: ADVAC LLC            Topic: NIAID

    PROJECT SUMMARY Current influenza (flu) vaccination inducing strain-specific immunity against variable hemagglutinin (HA) proteins is suboptimal for providing cross protection against antigenically-different epidemic strains and unanticipated new pandemic viruses. Development of an effective flu vaccine inducing enhanced cross protection against viruses with different HA variants is a high priorit ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Decellularized xenograft leaflet patch for pulmonary valve repair in pediatric patients

    SBC: TGen Tech, LLC            Topic: NIBIB

    Congenital heart disease affects approximately 40,000 newborns each year in the U.S. Valve repairs are needed for pulmonary valve, particularly for patients with the diagnoses of tetralogy of Fallot, tetralogy of Fallot with absent pulmonary valve, tetralogy of Fallot with AV canal, pulmonary valvar stenosis, and pulmonary valvar atresia. An additional group are patients with a prior repair of tet ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Multi-fold increase in the production of pharmaceutical insulin with Microbial Stem Cell Technology

    SBC: ASIMICA, INC.            Topic: 300

    PROJECT SUMMARY / ABSTRACT The goal of this project is to demonstrate the feasibility of a novel technology that is expected to boost yields from pharmaceutical industrial insulin production by greater than four-fold over conventional methods. Higher yields will lower production costs, generating savings that will ultimately be passed onto the millions of diabetic patients who require daily insuli ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a Novel MRI Contrast Agent for Early Detection of Alcoholic Steatohepatitis

    SBC: INLIGHTA BIOSCIENCES L.L.C.            Topic: 999

    Abstract Chronic liver disease (CLD) is a major cause of morbidity and mortality worldwide[1-4]. Hepatic fibrosis can develop in patients with any type of chronic liver disease (CLD), including alcoholic liver disease (ALD), hepatitis C, hepatitis B, nonalcoholic fatty liver disease (NAFLD) and autoimmune hepatitis. The major clinical consequences of cirrhosis are liver failure and hepatocellular ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Nanoparticles for detecting noradrenergic neurons in Alzheimer's Disease

    SBC: S G ENDOCRINE RESEARCH LLC            Topic: NIA

    Summary: Alzheimerandapos;s disease (AD) is a progressive neurological disorder that is marked by the presence of amyloid-ß plaques, neurofibrillary tangles and cognitive deficits. The economic impact of this disease is staggering and is expected to exceed $1 trillion dollars by the year 2050. Early diagnosis and treatment can substantially reduce the economic burden related to AD. Specifically, ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Developing Real-time Interaction and Motion Tracking in Immersive Virtual Reality for Telerehabilitation

    SBC: Move LLC            Topic: 102

    Abstract Unceasing breakthroughs in technology will shape future healthcare diagnosis, treatment, and delivery. Telerehabilitation delivers rehabilitative healthcare remotely to overcome spatial, temporal and economic barriers. Effectiveness of telerehabilitation has been seen for patients with orthopedic and traumatic injuries, degenerative central nervous system disorders, and cardiovascular dis ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a New Treatment for Diabetic Wounds

    SBC: NUTRIWYO LLC            Topic: NIDDK

    Abstract: Non-healing wounds affect ~25% of people with diabetes and represent a primary cause of amputation of lower limbs, which is an enormous clinical problem and a substantial economic burden. Given the lack of approved agents that effectively aid in the healing of diabetic wounds, a major need exists for developing novel pharmacological agents for treating diabetic wounds. Chronic diabetic w ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government